PTCT - PTC Therapeutics, Inc.
| Previous Close | 45.17 |
| Open | 45.00 |
| Bid | 43.48 x 900 |
| Ask | 50.00 x 800 |
| Day's Range | 43.52 - 45.70 |
| 52 Week Range | 27.53 - 48.99 |
| Volume | 266,091 |
| Avg. Volume | 566,276 |
| Market Cap | 2.552B |
| Beta (3Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.61 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.75 |
- Simply Wall St.
Does PTC Therapeutics, Inc. (NASDAQ:PTCT) Have A Volatile Share Price?
If you're interested in PTC Therapeutics, Inc. (NASDAQ:PTCT), then you might want to consider its beta (a measure of...
- Thomson Reuters StreetEvents
Edited Transcript of PTCT earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 PTC Therapeutics Inc Earnings Call
Motley FoolPTC Therapeutics (PTCT) Q2 2019 Earnings Call Transcript
PTCT earnings call for the period ending June 30, 2019.
- Zacks
PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -43.48% and 4.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
-Translarna™ approved in Brazil & PTC entered first annual contract with Ministry of Health- -Emflaza® receives FDA approval for a label expansion to treat DMD patients 2-5 years of age- -PTC expands gene ...
- PR Newswire
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
SOUTH PLAINFIELD, N.J., Aug. 5, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (BMY). Under the lease agreement, PTC will gain access to approximately 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, N.J. campus. PTC plans to further develop the biologics facility to support gene therapy production and foster innovation and employment in the community.
- PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., July 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on July 26, 2019 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
- Zacks
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results
SOUTH PLAINFIELD, N.J. , July 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2019 financial ...
- Simply Wall St.
Should You Worry About PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Cheque?
In 1998 Stuart Peltz was appointed CEO of PTC Therapeutics, Inc. (NASDAQ:PTCT). First, this article will compare CEO...
- Zacks
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
- PR Newswire
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
- Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases - SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics ...
- PR Newswire
PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion
SOUTH PLAINFIELD, N.J., June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translarna™ (ataluren) for the treatment of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) who are non-ambulatory. While the CHMP adopted a negative opinion of the extension, PTC was informed by EMA representatives that the European Public Assessment Report (EPAR) will be updated to clarify that patients who start Translarna while ambulatory are not required to discontinue treatment after loss of ambulation.
- Simply Wall St.
Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Benzinga
PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients
PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy ...
- PR Newswire
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old. Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5-years and older.
- PR Newswire
PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November ...
- PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, ...
- PR Newswire
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
SOUTH PLAINFIELD, N.J., May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year's funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
- PR Newswire
PTC Therapeutics and MRI Interventions Announce Strategic Investment
SOUTH PLAINFIELD, N.J. and IRVINE, Calif., May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and MRI Interventions, Inc. (MRIC) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI have also entered into a supply agreement for MRI's neurosurgical devices for PTC's current and future gene therapy programs. MRI is a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy.
- Thomson Reuters StreetEvents
Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 PTC Therapeutics Inc Earnings Call
- PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill ...
